Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an ...

When Cathy Tie started Locke Bio, a Culver City-based digital health startup, she had spent years as a venture capitalist seeing a trend in the digital ...

Persistently high rates of both type 1 and 2 diabetes as well as racial health disparities are indicators of lingering gaps in care for Indigenous communities.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Find insights on China’s healthcare sector, Thomson Medical Group, Cochlear, and more in the latest Market Talks covering the ...

To McIntosh, the most surprising bankruptcy of 2024 was Eiger BioPharmaceuticals, a metabolic disease biotech that was ...

Available exclusively through Fox Pharma, the latest aesthetic innovation, VITARAN harnesses the power of trout DNA for a ...

What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after ...

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

FHI 360 is conducting a fully-funded Phase 1 trial to investigate pharmacokinetics, removability, safety and tolerability of Casea S with support from a foundation grant (ClinicalTrials.gov ID: ...